SCHEDULE: Wellington Management Discloses Stake in Apogee Therapeutics

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 0.9% of Apogee Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• Wellington Management Group LLP, along with its subsidiaries Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP, has filed a Schedule 13G.
• This filing indicates beneficial ownership of Apogee Therapeutics, Inc. common stock.
• The reporting entities collectively own 564,326 shares, representing 0.9% of the class of securities.
• The shares are held by clients of various Wellington investment advisers, with Wellington Investment Advisors Holdings LLP controlling these advisers.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, indicating a standard disclosure of institutional ownership without immediate positive or negative implications for the company's stock price.

Positives

• Significant institutional investor, Wellington Management, has taken a position in Apogee Therapeutics, Inc., which can be seen as a vote of confidence.
• The filing indicates a passive investment strategy, suggesting a focus on the company's long-term prospects rather than activist intentions.

Negatives

• The reported stake of 0.9% is relatively small, suggesting it may not represent a significant conviction or influence on the company's strategic direction.

Risks

• The filing does not explicitly mention any risks associated with the investment itself, but general market risks for biotechnology companies apply.
• Potential for future changes in Wellington's holdings, which could impact share price if significant buying or selling occurs.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Apogee Therapeutics, Inc. The future outlook for the investment depends on the performance of Apogee Therapeutics, Inc. and Wellington Management's investment strategy.

Industry Context

StockSavvy.ai notes that institutional ownership filings like this Schedule 13G are common in the biotechnology sector, reflecting the significant capital required for drug development and the interest from large asset managers in promising therapeutic companies.

Comparison to Industry Standards

• A 0.9% stake by a major asset manager like Wellington Management is a common entry point for institutional investors in publicly traded companies, particularly in the biotech space where initial stakes can be modest before conviction grows.
• Many large institutional investors, such as BlackRock, Vanguard, and State Street, hold similar or larger passive stakes in publicly traded companies across various sectors.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's presence, which can be perceived positively, but the small percentage may limit immediate impact.
• Management: The filing indicates that Wellington Management is not seeking to influence control, allowing current management to continue its strategic direction.
• Creditors: No direct impact is indicated.

Next Steps

• Wellington Management will continue to monitor Apogee Therapeutics, Inc. and may adjust its holdings based on market conditions and company performance.
• Apogee Therapeutics, Inc. will continue its operations and development activities, which will be reflected in future SEC filings.

Key Dates

Keywords

Apogee Therapeutics, Wellington Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Biotechnology